Unique ID issued by UMIN | UMIN000020486 |
---|---|
Receipt number | R000023555 |
Scientific Title | The analysis of the impact of basal insulin stabiity on day-by-day blood glucose variability |
Date of disclosure of the study information | 2016/01/07 |
Last modified on | 2016/06/07 10:33:05 |
The analysis of the impact of basal insulin stabiity on day-by-day blood glucose variability
The analysis of the impact of basal insulin stabiity on day-by-day blood glucose variability
The analysis of the impact of basal insulin stabiity on day-by-day blood glucose variability
The analysis of the impact of basal insulin stabiity on day-by-day blood glucose variability
Japan |
Type 2 diabetes
Endocrinology and Metabolism |
Others
NO
The aim of this crossover study, comparison of long and conventional acting basal insulin, is to evaluate the effect on day-by-day blood glucose variability.
Efficacy
The average of 2 times of mean of daily differences (MODD)
Day-by-day variability of fasting blood glucose
Interventional
Cross-over
Randomized
Individual
Open -no one is blinded
Active
2
Treatment
Medicine |
In the first course, insulin glargine U100 is used for 4 weeks. After the treatment of insulin glargine U100, the CGM examination is underwent. In the second course, insulin glargine U300 is used for 4 weeks. After the treatment of insulin glargine U300, the CGM examination is underwent. Insulin dose is adjusted at the beginning and 2 weeks of each course according to the titration method.
In the first course, insulin glargine U300 is used for 4 weeks. After the treatment of insulin glargine U300, the CGM examination is underwent. In the second course, insulin glargine U100 is used for 4 weeks. After the treatment of insulin glargine U100, the CGM examination is underwent. Insulin dose is adjusted at the beginning and 2 weeks of each course according to the titration method.
18 | years-old | <= |
75 | years-old | > |
Male and Female
1) Type 2 diabetic patient who has injected glargine U100 for more than 12 weeks.
2) HbA1c less than 9% within 4 weeks prior to entry
3) Patient who can undergo self monitoring blood glucose before each insulin injection and equip continuous glucose monitoring
1) severe ketosis, coma, or reduced level of con- sciousness due to diabetes within the past 6 months
2) Patients who may have been pregnant or pregnant women
3) Patients with abnormal aspartate aminotransferase/alanine aminotransferase elevation (3 X the upper limit of normal)
4) Patients with moderate or severe renal dysfunction (BUN more than 25mg/dL or serum creatinine more than 2.0 mg/dL)
16
1st name | |
Middle name | |
Last name | Masaya Sakamoto |
Jikei University School of Medicine
Division of Diabetes, Metabolism and Endocrinology
3-25-8 Nishi-Shinbashi, Minato-ku, Tokyo
03-3433-1111
m-sakamoto@umin.ac.jp
1st name | |
Middle name | |
Last name | Masaya Sakamoto |
Jikei University School of Medicine
Division of Diabetes, Metabolism and Endocrinology
3-25-8 Nishi-Shinbashi, Minato-ku, Tokyo
03-3433-1111
m-sakamoto@umin.ac.jp
Division of Diabetes, Metabolism and Endocrinology, Jikei University School of Medicine
Division of Diabetes, Metabolism and Endocrinology, Jikei University School of Medicine
Self funding
NO
2016 | Year | 01 | Month | 07 | Day |
Unpublished
Completed
2015 | Year | 11 | Month | 01 | Day |
2016 | Year | 01 | Month | 04 | Day |
2016 | Year | 01 | Month | 07 | Day |
2016 | Year | 06 | Month | 07 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000023555
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |